🇺🇸 FDA
Patent

US 7618623

Hybrid adeno-retroviral vector for the transfection of cells

granted A61KA61K35/13A61K48/00

Quick answer

US patent 7618623 (Hybrid adeno-retroviral vector for the transfection of cells) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Nov 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Nov 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K35/13, A61K48/00, A61P, A61P43/00